An observational study in Endometrial Receptivity, sponsored by Instituto Valenciano de Infertilidad, IVI VALENCIA. Completed at 1 site in Spain. Open to female participants aged 18 Years to 44 Years. Per ClinicalTrials.gov, last updated 2023-10-24.
Sponsored by Instituto Valenciano de Infertilidad, IVI VALENCIA · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 387 studies in Obesity with a site in Spain — 92 open to participants now, 131 under way, 43 of them phase 3. Obesity · Spain.
Among the 387 studies in Obesity with a site in Spain, this one is the 39th largest by enrollment of the 57 observational ones that give a count, is one of 26 that started in 2018, is one of 57 observational ones, and was the 108th registered.
11,536 studies on the registry are indexed under Obesity; 2,042 are open to participants now.
Browse Obesity studies →92 of the 387 studies in Obesity with a site in Spain are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Spain, United States, Brazil and 7 more countries
Ages 18+
Eli Lilly and Company · Sites in Spain, United States, Belgium and 7 more countries
Ages 6–11
AstraZeneca · Sites in Spain, United States, Argentina and 13 more countries
Ages 18+
Novo Nordisk A/S · Sites in Spain, United States, Belgium and 7 more countries
Ages 18+
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud · Sites in Spain
Ages 18–65
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.
This study: 18 Years to 44 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
387 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 24 · Phase 3 79 · Phase 4 7
First in 2001; this study’s year is marked. 26 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 80 is below the median of 115 across 2,158 observational studies indexed under Obesity.
Median enrollment 123 across the 329 interventional studies, 128 across the 57 observational. Of the 208 that completed or were terminated, 26 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
119 of 387 have an industry lead sponsor. The 10 most frequent:
Instituto Valenciano de Infertilidad, IVI VALENCIA is the lead sponsor of 72 studies on the registry; 8 are open to participants now.
Instituto Valenciano de Infertilidad, IVI VALENCIA has 3 studies filed under Obesity — fewer than ten, so there is no comparison to draw.
32 of the studies in Obesity with a site in Spain that are under way reach primary completion within a year, 12 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06914895Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06962280Phase 3Eli Lilly and CompanyA Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT07332273Phase 3Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y SaludLevothyroxine as Adjuvant to a Hypocaloric Diet for the Treatment of Obesity. | 2026-11 |
| NCT06858839Phase 3AmgenEvaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT06672549Phase 3Eli Lilly and CompanyA Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) | 2027-02 |
Add all 32 to your calendar (.ics) → With an account.
Among the 387 studies in Obesity with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this project is the identification and quantification of the main bacterial communities present in the endometrial microbiota in obese infertile patients, to assess if there is an alteration of their composition dependent on the body mass index, and if such alteration it could influence the reduction of endometrial receptivity, demonstrated in obese women. If obese patients have an altered digestive microbiota and, at the same time, a lower endometrial receptivity, the investigator want to assess whether such reduction in receptivity may depend on an alteration in the endometrial microbiota, which in non-obese infertile patients has been shown to negatively influence the reproductive results
The main objective of our study is to compare the composition of the endometrial microbiota between patients with normal weight and patients with obesity.
A. Secondary Objectives/research questions
Infertile patients with normal weight (BMI: between 18.50 and 29.99) and obesity (Class I: BMI between 30 and 34.99 Kg / m2, Class II: BMI between 35 and 39.99 Kg / m2, Class III: BMI> 40 Kg / m2) subjected to Hormonal Replacement Therapy (HRT).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI: Between 18.50 and 29.99 kg/m2
BMI between 30 and 34.99 Kg/m2
BMI between 35 and 39.99 Kg/m2
BMI\> 40 Kg/m2
Microbiological analysis of endometrial fluid samples through massive sequencing
Identification and quantification of the main bacterial communities present in the endometrial microbiota of obese and normal-weight infertile patients through the analysis of the endometrial fluid.
Time frame: 14 months
Microbiological analysis of saliva samples through massive sequencing.
Identification and quantification of the main bacterial communities present in the oral microbiota of obese and normal-weight infertile patients through the analysis of saliva samples.
Time frame: 14 months
Microbiological analysis of feces samples through massive sequencing.
Identification and quantification of the main bacterial communities present in the intestinal microbiota of obese and normal-weight infertile patients through the analysis of feces samples.
Time frame: 14 months
Analysis of endometrial receptivity using niERA
Analysis of the optimal implantation window through the study of the expression of 238 genes involved in receptivity using endometrial fluid samples.
Time frame: 13 months
Plan to share: No
No publications or documents are linked to this record.
Ran from May 2018 to primary completion in Sep 2021, 39 months.
Of 793 non-industry observational studies under Obesity, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 106. This study's 39 months is close to that.
Counting every sponsor, half of 838 studies reached it within 39 months; a quarter within 17 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Instituto Valenciano de Infertilidad, IVI VALENCIA